scholarly journals Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes

2021 ◽  
Author(s):  
Catherine C. Robertson ◽  
Jamie R. J. Inshaw ◽  
Suna Onengut-Gumuscu ◽  
Wei-Min Chen ◽  
David Flores Santa Cruz ◽  
...  
2018 ◽  
Vol 50 (10) ◽  
pp. 1366-1374 ◽  
Author(s):  
Harm-Jan Westra ◽  
Marta Martínez-Bonet ◽  
Suna Onengut-Gumuscu ◽  
Annette Lee ◽  
Yang Luo ◽  
...  

2015 ◽  
Vol 47 (4) ◽  
pp. 381-386 ◽  
Author(s):  
Suna Onengut-Gumuscu ◽  
◽  
Wei-Min Chen ◽  
Oliver Burren ◽  
Nick J Cooper ◽  
...  

Author(s):  
C.C. Robertson ◽  
J.R.J. Inshaw ◽  
S. Onengut-Gumuscu ◽  
W.M. Chen ◽  
D. Flores Santa Cruz ◽  
...  

AbstractWe report the largest and most ancestrally diverse genetic study of type 1 diabetes (T1D) to date (61,427 participants), yielding 152 regions associated to false discovery rate < 0.01, including 36 regions associated to genome-wide significance for the first time. Credible sets of disease-associated variants are specifically enriched in immune cell accessible chromatin, particularly in CD4+ effector T cells. Colocalization with chromatin accessibility quantitative trait loci (QTL) in CD4+ T cells identified five regions where differences in T1D risk and chromatin accessibility are potentially driven by the same causal variant. Allele-specific chromatin accessibility further refined the set of putative causal variants with functional relevance in CD4+ T cells and integration of whole blood expression QTLs identified candidate T1D genes, providing high-yield targets for mechanistic follow-up. We highlight rs72938038 in BACH2 as a candidate causal T1D variant, where the T1D risk allele leads to decreased enhancer accessibility and BACH2 expression in T cells. Finally, we prioritise potential drug targets by integrating genetic evidence, functional genomic maps, and immune protein-protein interactions, identifying 12 genes implicated in T1D that have been targeted in clinical trials for autoimmune diseases. These findings provide an expanded genomic landscape for T1D, including proposed genetic regulatory mechanisms of T1D-associated variants and genetic support for therapeutic targets for immune intervention.


2017 ◽  
Author(s):  
Harm-Jan Westra ◽  
Marta Martinez Bonet ◽  
Suna Onengut ◽  
Annette Lee ◽  
Yang Luo ◽  
...  

We fine-mapped 76 rheumatoid arthritis (RA) and type 1 diabetes (T1D) loci outside of the MHC. After sequencing 799 1kb regulatory (H3K4me3) regions within these loci in 568 individuals, we observed accurate imputation for 89% of common variants. We fine-mapped1,2 these loci in RA (11,475 cases, 15,870 controls)3, T1D (9,334 cases and 11,111 controls) 4 and combined datasets. We reduced the number of potential causal variants to ≤5 in 8 RA and 11 T1D loci. We identified causal missense variants in five loci (DNASE1L3, SIRPG, PTPN22, SH2B3 and TYK2) and likely causal non-coding variants in six loci (MEG3, TNFAIP3, CD28/CTLA4, ANKRD55, IL2RA, REL/PUS10). Functional analysis confirmed allele specific binding and differential enhancer activity for three variants: the CD28/CTLA4 rs117701653 SNP, the TNFAIP3 rs35926684 indel, and the MEG3 rs34552516 indel. This study demonstrates the potential for dense genotyping and imputation to pinpoint missense and non-coding causal alleles.


2013 ◽  
Vol 24 (9-10) ◽  
pp. 358-375 ◽  
Author(s):  
Emma E. Hamilton-Williams ◽  
Daniel B. Rainbow ◽  
Jocelyn Cheung ◽  
Mikkel Christensen ◽  
Paul A. Lyons ◽  
...  

2020 ◽  
Author(s):  
Tatsuhiko Naito ◽  
Ken Suzuki ◽  
Jun Hirata ◽  
Yoichiro Kamatani ◽  
Koichi Matsuda ◽  
...  

Conventional HLA imputation methods drop their performance for infrequent alleles, which reduces reliability of trans-ethnic MHC fine-mapping due to inter-ethnic heterogeneity in allele frequency spectra. We developed DEEP*HLA, a deep learning method for imputing HLA genotypes. Through validation using the Japanese and European HLA reference panels (n = 1,118 and 5,112), DEEP*HLA achieved the highest accuracies in both datasets (0.987 and 0.976) especially for low-frequency and rare alleles. DEEP*HLA was less dependent of distance-dependent linkage disequilibrium decay of the target alleles and might capture the complicated region-wide information. We applied DEEP*HLA to type 1 diabetes GWAS data of BioBank Japan (n = 62,387) and UK Biobank (n = 356,855), and successfully disentangled independently associated class I and II HLA variants with shared risk between diverse populations (the top signal at HLA-DRβ1 amino acid position 71; P = 6.2 × 10-119). Our study illustrates a value of deep learning in genotype imputation and trans-ethnic MHC fine-mapping.


Diabetes ◽  
2014 ◽  
Vol 63 (12) ◽  
pp. 4360-4368 ◽  
Author(s):  
M. J. Tomlinson ◽  
A. Pitsillides ◽  
R. Pickin ◽  
M. Mika ◽  
K. L. Keene ◽  
...  

2020 ◽  
Author(s):  
Apostolia Topaloudi ◽  
Zoi Zagoriti ◽  
Alyssa C. Flint ◽  
Melanie B. Martinez ◽  
Zhiyu Yang ◽  
...  

AbstractBackgroundMyasthenia Gravis (MG) is a rare autoimmune disorder affecting the neuromuscular junction. Here, we investigate the genetic architecture of MG performing a genomewide association study (GWAS) of the largest MG dataset analyzed to date.MethodsWe integrated GWAS from three different datasets (1,401 cases, 3,508 controls) and performed MG GWAS and onset-specific analyses. We also carried out HLA fine-mapping, gene-based, gene ontology and tissue enrichment analyses and investigated genetic correlation to other autoimmune disorders.FindingsWe observed the strongest MG association to TNFRSF11A (rs4369774, p=1.09×10−13; OR=1.4). Gene-based analysis revealed AGRN as a novel MG susceptibility gene. HLA fine-mapping pointed to two independent loci significantly associated with MG: HLA-DRB1 (with a protective role) and HLA-B. MG onset-specific analysis, reveals differences in the genetic architecture of Early-Onset vs Late-Onset MG. Furthermore, we find MG to be genetically correlated with Type 1 Diabetes, Rheumatoid Arthritis and late-onset Vitiligo.InterpretationOverall, our results are consistent with previous studies highlighting the role of the HLA and TNFRSF11A in MG etiology and different risk genes in EOMG vs LOMG. Furthermore, our gene-based analysis implicates, for the first time, AGRN as a MG susceptibility locus. AGRN encodes agrin, which is involved in neuromuscular junction formation. Mutations in AGRN have been found to underlie congenital myasthenic syndrome. Gene ontology analysis suggests an intriguing role for symbiotic processes in MG etiology. We also uncover genetic correlation of MG to Type 1 Diabetes, Rheumatoid Arthritis and late-onset Vitiligo, pointing to shared underlying genetic mechanisms.FundingThis work was supported by NSF award #1715202, the European Social Fund and Greek funds through the National Strategic Reference Framework (NSRF) THALES Programme 2012–2015 and the NSRF ARISTEIA II Programme 2007–2013 to PP, and grants from the Association Francaise contre les Myopathies (AFM, Grant No. 80077) to ST.Research in contextEvidence before this studyMyasthenia Gravis (MG) is a complex disease caused by the interaction of genetic and environmental factors that lead to autoimmune activation. Previous studies have shown that the human leukocyte antigen (HLA) displays the most robust genetic association signals to MG. Additional susceptibility genes that have emerged through genomewide association studies (GWAS), include CTLA4 and TNFRSF11A. Previous studies also support the hypothesis of distinct risk loci underlying Early-Onset versus Late-Onset MG subgroups (EOMG vs LOMG). For instance, PTPN22 and TNIP1 genes have been implicated in EOMG and ZBTB10 in LOMG. In the GWAS studies published so far, HLA and TNFRSF11A associations appear to be confirmed; however, the association of other implicated genes still requires replication.Added value of this studyWe present the largest GWAS for MG to date, integrating three different datasets. We identify AGRN as a novel MG risk locus and replicate previously reported susceptibility loci, including HLA, TNFRSF11A, and CTLA4. Our analysis also supports the existence of a different genetic architecture in EOMG vs LOMG and identifies a region between SRCAP and FBRS as a novel EOMG risk locus. Additionally, through HLA fine-mapping, we observe different HLA genes implicated in EOMG vs LOMG (HLA-B and HLA-DRB1 respectively). Finally, we detect positive genetic correlation of MG with other autoimmune disorders including Type 1 Diabetes, Rheumatoid Arthritis, and late-onset Vitiligo, suggesting a shared genetic basis across them.Implications of all the available evidenceOur study sheds light into the etiology of MG identifying AGRN as a novel risk locus. AGRN encodes agrin, a protein with a significant role in the formation of the neuromuscular junction and mutations in this gene have been associated with congenital myasthenic syndrome. Our findings hint to an intriguing hypothesis of symbiotic processes underlying MG pathogenesis and points to muscle growth and development in EOMG and steroid hormones synthesis in LOMG. The observed genetic correlations between MG and certain other autoimmune disorders could possibly underlie comorbidity patterns across this group of disorders.


2019 ◽  
Author(s):  
Anna Hutchinson ◽  
Hope Watson ◽  
Chris Wallace

AbstractGenome Wide Association Studies (GWAS) have successfully identified thousands of loci associated with human diseases. Bayesian genetic fine-mapping studies aim to identify the specific causal variants within GWAS loci responsible for each association, reporting credible sets of plausible causal variants, which are interpreted as containing the causal variant with some “coverage probability”.Here, we use simulations to demonstrate that the coverage probabilities are over-conservative in most fine-mapping situations. We show that this is because fine-mapping data sets are not randomly selected from amongst all causal variants, but from amongst causal variants with larger effect sizes. We present a method to re-estimate the coverage of credible sets using rapid simulations based on the observed, or estimated, SNP correlation structure, we call this the “corrected coverage estimate”. This is extended to find “corrected credible sets”, which are the smallest set of variants such that their corrected coverage estimate meets the target coverage.We use our method to improve the resolution of a fine-mapping study of type 1 diabetes. We found that in 27 out of 39 associated genomic regions our method could reduce the number of potentially causal variants to consider for follow-up, and found that none of the 95% or 99% credible sets required the inclusion of more variants – a pattern matched in simulations of well powered GWAS.Crucially, our correction method requires only GWAS summary statistics and remains accurate when SNP correlations are estimated from a large reference panel. Using our method to improve the resolution of fine-mapping studies will enable more efficient expenditure of resources in the follow-up process of annotating the variants in the credible set to determine the implicated genes and pathways in human diseases.Author summaryPinpointing specific genetic variants within the genome that are causal for human diseases is difficult due to complex correlation patterns existing between variants. Consequently, researchers typically prioritise a set of plausible causal variants for functional validation - these sets of putative causal variants are called “credible sets”. We find that the probabilistic interpretation that these credible sets do indeed contain the true causal variant is variable, in that the reported probabilities often underestimate the true coverage of the causal variant in the credible set. We have developed a method to provide researchers with a “corrected coverage estimate” that the true causal variant appears in the credible set, and this has been extended to find “corrected credible sets”, allowing for more efficient allocation of resources in the expensive follow-up laboratory experiments. We used our method to reduce the number of genetic variants to consider as causal candidates for follow-up in 27 genomic regions that are associated with type 1 diabetes.


Sign in / Sign up

Export Citation Format

Share Document